MacroGenics Inc (MGNX) - Total Assets
Based on the latest financial reports, MacroGenics Inc (MGNX) holds total assets worth $256.85 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore MGNX cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
MacroGenics Inc - Total Assets Trend (2011–2025)
This chart illustrates how MacroGenics Inc's total assets have evolved over time, based on quarterly financial data. See shareholders equity of MacroGenics Inc for net asset value and shareholders' equity analysis.
MacroGenics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
MacroGenics Inc's total assets of $256.85 Million consist of 85.6% current assets and 14.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.3% |
| Accounts Receivable | $13.37 Million | 5.2% |
| Inventory | $7.91 Million | 3.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how MacroGenics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MacroGenics Inc (MGNX) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MacroGenics Inc's current assets represent 85.6% of total assets in 2025, a decrease from 93.6% in 2011.
- Cash Position: Cash and equivalents constituted 22.3% of total assets in 2025, down from 88.1% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 5.2% of total assets.
MacroGenics Inc Competitors by Total Assets
Key competitors of MacroGenics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.40 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
|
Zhejiang Shouxiangu Pharm Co
SHG:603896
|
China | CN¥3.22 Billion |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399
|
China | CN¥3.65 Billion |
MacroGenics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.10 | 3.92 | 7.06 |
| Quick Ratio | 4.92 | 3.92 | 6.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $176.83 Million | $161.96 Million | $321.68 Million |
MacroGenics Inc - Advanced Valuation Insights
This section examines the relationship between MacroGenics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.52 |
| Latest Market Cap to Assets Ratio | 0.85 |
| Asset Growth Rate (YoY) | -1.8% |
| Total Assets | $256.85 Million |
| Market Capitalization | $218.65 Million USD |
Valuation Analysis
Near Book Valuation: The market values MacroGenics Inc's assets close to their book value (0.85x), suggesting investors view the company's assets at approximately fair value.
Slight Asset Contraction: MacroGenics Inc's assets decreased by 1.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for MacroGenics Inc (2011–2025)
The table below shows the annual total assets of MacroGenics Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $256.85 Million | -1.84% |
| 2024-12-31 | $261.65 Million | -12.32% |
| 2023-12-31 | $298.42 Million | +3.08% |
| 2022-12-31 | $289.51 Million | -13.64% |
| 2021-12-31 | $335.25 Million | -11.48% |
| 2020-12-31 | $378.74 Million | +21.20% |
| 2019-12-31 | $312.50 Million | -5.91% |
| 2018-12-31 | $332.13 Million | -11.17% |
| 2017-12-31 | $373.88 Million | +20.12% |
| 2016-12-31 | $311.26 Million | -13.36% |
| 2015-12-31 | $359.27 Million | +106.61% |
| 2014-12-31 | $173.89 Million | +38.24% |
| 2013-12-31 | $125.78 Million | +134.03% |
| 2012-12-31 | $53.75 Million | -14.25% |
| 2011-12-31 | $62.68 Million | -- |
About MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical tri… Read more